Search

everythinglearnresearchcommunity

for

Search:↓

A user humorously shared their appearance three days after a hair transplant, sparking jokes and memes about their head shape. They remained positive, acknowledging the swelling and hoping for improvement.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

A 21-year-old male experienced significant hair regrowth using minoxidil 5% topical, oral finasteride 1mg, derma stamping, and ketoconazole shampoo over several months. He reported no side effects and remains optimistic about further progress.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

2-deoxy-D-ribose is being explored as a hair loss treatment but is not proven effective in humans and may be costly and inconvenient. Minoxidil remains the most effective treatment.

The user switched from finasteride to dutasteride for stronger hair loss treatment, despite initial success with finasteride. They experienced significant shedding with dutasteride but remain hopeful for regrowth, emphasizing patience and the importance of giving treatments time to work.

Hair loss negatively affects mental health, causing anxiety and depression. Minoxidil and finasteride are discussed as treatments, but side effects and mental health concerns remain.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is considering adding liposomal dutasteride to their hair loss treatment, which currently includes topical finasteride and minoxidil. They are exploring different concentrations and application frequencies to enhance hair retention and are also planning to continue using Rogaine.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

A 21-year-old male used low-dose 5% topical Minoxidil inconsistently for four months, resulting in stopped hair shedding and improved hair density, though the hairline remained unchanged. Users discussed the potential use of finasteride and other treatments, with some suggesting consulting a dermatologist for further advice.

Finasteride typically helps maintain the existing hairline and taking 0.5mg MWF is considered effective. Hair transplants remain an option if further treatment is needed.

Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.

Minoxidil foam and oral finasteride resulted in significant hair regrowth, especially on the hairline, with no side effects from finasteride. The user applied Rogaine 5% for minoxidil.

A 34-year-old male is experiencing hair loss on the sides of his head, with inflammation and itchiness, while the top remains thick. He is using topical dutasteride and keto shampoo to address the issue.

A 22-year-old male has been using Minoxidil for 2.5 years and Finasteride for 8 months without significant improvement in hair loss. Despite adding supplements and other treatments, hair density remains low, and he seeks advice on further options.

A 34-year-old male has been using a topical minoxidil and finasteride solution for hair loss and was prescribed oral finasteride by a dermatologist. He questions the necessity of monthly consultations since the prescription remains unchanged.

Microneedling is supported by research as an effective adjuvant treatment for hair loss, especially when combined with Minoxidil or Finasteride, with minimal side effects if done properly. Concerns about long-term safety and potential risks like infection or fibrosis remain, but many users report positive results.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

A 30-year-old is using dutasteride daily, ketoconazole shampoo twice a week, and started topical minoxidil and dermastamping six months ago for hair loss. The treatment has improved hair density, but significant hairline recession remains, and a hair transplant is suggested for further improvement.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

The user has been using finasteride, dutasteride, minoxidil, and RU58841 for hair loss but is experiencing worsening hair density despite treatment. They are frustrated and confused as their hairline remains unchanged, but the overall hair thickness has decreased significantly.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.